Patents Assigned to XENOTHERA
  • Method for producing polyclonal antibodies with improved complement-dependent cytotoxicity
    Patent number: 11725044
    Abstract: The present invention relates to polyclonal antibodies directed against at least one non-human biological pathogen, or against at least one molecule derived from said pathogen, towards a human or a non-human animal organism, wherein the said polyclonal antibodies are devoid of an antigenic determinant selected in a group comprising (i) N-glycolneuraminic acid (Neu5Gc) and/or (ii) a-1,3-galactose, and their use as a medicament.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: August 15, 2023
    Assignee: Xenothera
    Inventors: Odile Duvaux, Jean-Paul Soulillou
  • COMPOSITION WITH REDUCED IMMUNOGENICITY
    Publication number: 20170240616
    Abstract: The present invention relates to polyclonal antibodies directed against at least one non-human biological pathogen, or against at least one molecule derived from said pathogen, towards a human or a non-human animal organism, wherein the said polyclonal antibodies are devoid of an antigenic determinant selected in a group comprising (i) N-glycolneuraminic acid (Neu5Gc) and/or (ii) a-1,3-galactose, and their use as a medicament.
    Type: Application
    Filed: October 15, 2015
    Publication date: August 24, 2017
    Applicant: XENOTHERA
    Inventors: Odile DUVAUX, Jean-Paul SOULILLOU